Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H20FN5O4 |
Molecular Weight | 401.3916 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CO\N=C1/CN(CC12CNC2)C3=NC4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O
InChI
InChIKey=ZNPOCLHDJCAZAH-OEAKJJBVSA-N
InChI=1S/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14+
Molecular Formula | C19H20FN5O4 |
Molecular Weight | 401.3916 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Zabofloxacin (also known as DW-224a), a fluoroquinolone antibiotic agent, is a dual inhibitor of both DNA gyrase and topoisomerase IV of Streptococcus pneumonia. Zabofloxacin successfully has completed phase III clinical trial in patients with acute bacterial exacerbation of the chronic obstructive pulmonary disease. In addition, in May 2012, IASO terminated phase II trial of oral zabofloxacin capsules in patients with moderate-to-severe community-acquired pneumonia due to financial considerations.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent. | 2004 Nov |
|
Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains. | 2008 Sep |
|
DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae. | 2010 Jul |
|
New treatment options for lower respiratory tract infections. | 2017 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01658020
Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:54:01 GMT 2023
by
admin
on
Sat Dec 16 16:54:01 GMT 2023
|
Record UNII |
LV66BA6V2G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C795
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
LV66BA6V2G
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
PRIMARY | |||
|
DB12479
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
PRIMARY | |||
|
C82232
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
PRIMARY | |||
|
Zabofloxacin
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
PRIMARY | |||
|
C480202
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
PRIMARY | |||
|
5249
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
PRIMARY | |||
|
8594
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
PRIMARY | |||
|
219680-11-2
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
PRIMARY | |||
|
100000182642
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
PRIMARY | |||
|
SUB196891
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107811
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
PRIMARY | |||
|
10388396
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
PRIMARY | |||
|
DTXSID10870251
Created by
admin on Sat Dec 16 16:54:03 GMT 2023 , Edited by admin on Sat Dec 16 16:54:03 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|